These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

448 related items for PubMed ID: 17692090

  • 1. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
    Salani R, Kurman RJ, Giuntoli R, Gardner G, Bristow R, Wang TL, Shih IM.
    Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
    [Abstract] [Full Text] [Related]

  • 2. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
    Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD.
    J Pathol; 2010 May; 221(1):49-56. PubMed ID: 20229506
    [Abstract] [Full Text] [Related]

  • 3. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
    Fransson Å, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N.
    J Ovarian Res; 2016 May 14; 9(1):27. PubMed ID: 27179933
    [Abstract] [Full Text] [Related]

  • 4. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
    Canet B, Pons C, Espinosa I, Prat J.
    Hum Pathol; 2011 Jun 14; 42(6):833-9. PubMed ID: 21208644
    [Abstract] [Full Text] [Related]

  • 5. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P, Mueting SR, Carlson MJ, Goodheart MJ, Button AM, Mott SL, Dai D, Thiel KW, Devor EJ, Leslie KK.
    Int J Oncol; 2015 Feb 14; 46(2):607-18. PubMed ID: 25385265
    [Abstract] [Full Text] [Related]

  • 6. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih IeM.
    Clin Cancer Res; 2004 Oct 01; 10(19):6432-6. PubMed ID: 15475429
    [Abstract] [Full Text] [Related]

  • 7. Poor survival with wild-type TP53 ovarian cancer?
    Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM.
    Gynecol Oncol; 2013 Sep 01; 130(3):565-9. PubMed ID: 23800698
    [Abstract] [Full Text] [Related]

  • 8. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
    Singer G, Stöhr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, Shih IeM.
    Am J Surg Pathol; 2005 Feb 01; 29(2):218-24. PubMed ID: 15644779
    [Abstract] [Full Text] [Related]

  • 9. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A.
    Exp Mol Pathol; 2013 Oct 01; 95(2):235-41. PubMed ID: 23965232
    [Abstract] [Full Text] [Related]

  • 10. TP53 gene status and human papilloma virus infection in response to platinum plus taxane-based chemotherapy of epithelial ovarian carcinomas.
    Malisic E, Jankovic R, Jakovljevic K, Radulovic S.
    J BUON; 2011 Oct 01; 16(4):701-7. PubMed ID: 22331725
    [Abstract] [Full Text] [Related]

  • 11. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.
    Vang R, Shih IeM, Salani R, Sugar E, Ayhan A, Kurman RJ.
    Am J Surg Pathol; 2008 Nov 01; 32(11):1667-74. PubMed ID: 18769340
    [Abstract] [Full Text] [Related]

  • 12. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
    Gadducci A, Di Cristofano C, Zavaglia M, Giusti L, Menicagli M, Cosio S, Naccarato AG, Genazzani AR, Bevilacqua G, Cavazzana AO.
    Anticancer Res; 2006 Nov 01; 26(1B):687-93. PubMed ID: 16739339
    [Abstract] [Full Text] [Related]

  • 13. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH, Ailawadi M, Colitti C, Muto MG, Deavers M, Silva EG, Berkowitz RS, Mok SC, Gershenson DM.
    Cancer Res; 2001 Oct 01; 61(19):7264-7. PubMed ID: 11585764
    [Abstract] [Full Text] [Related]

  • 14. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
    Yen MJ, Hsu CY, Mao TL, Wu TC, Roden R, Wang TL, Shih IeM.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):827-31. PubMed ID: 16467095
    [Abstract] [Full Text] [Related]

  • 15. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
    Santillan A, Kim YW, Zahurak ML, Gardner GJ, Giuntoli RL, Shih IM, Bristow RE.
    Int J Gynecol Cancer; 2007 Feb 01; 17(3):601-6. PubMed ID: 17504374
    [Abstract] [Full Text] [Related]

  • 16. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
    McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB.
    Mod Pathol; 2012 May 01; 25(5):740-50. PubMed ID: 22282309
    [Abstract] [Full Text] [Related]

  • 17. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, Sharma R, Russell P, Kennedy C, Fereday S, Hung J, Galletta L, Hogg R, Wain GV, Brand A, Balleine R, MacConaill L, Palescandolo E, Hunter SM, Campbell I, Dobrovic A, Wong SQ, Do H, Clarke CL, Harnett PR, Bowtell DD, deFazio A, Australian Ovarian Cancer Study (AOCS).
    Clin Cancer Res; 2014 Dec 15; 20(24):6618-30. PubMed ID: 25316818
    [Abstract] [Full Text] [Related]

  • 18. TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.
    Montemorano L, Shultz ZB, Farooque A, Hyun M, Chappell RJ, Hartenbach EM, Lang JD.
    Gynecol Oncol; 2024 Jul 15; 186():26-34. PubMed ID: 38555766
    [Abstract] [Full Text] [Related]

  • 19. Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
    Holý P, Hlaváč V, Šeborová K, Šůsová S, Tesařová T, Rob L, Hruda M, Bouda J, Bartáková A, Mrhalová M, Kopečková K, Al Obeed Allah M, Špaček J, Sedláková I, Souček P, Václavíková R.
    Int J Cancer; 2024 Jul 01; 155(1):104-116. PubMed ID: 38447012
    [Abstract] [Full Text] [Related]

  • 20. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IeM, Kurman RJ.
    Int J Gynecol Pathol; 2016 Jan 01; 35(1):48-55. PubMed ID: 26166714
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.